Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search
  1. NCI-F Publications

Search
  1. Year Published:

Your search returned 10 results.
User Information
Export Records
  1. 1.   Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs
  2. LeBlanc, Amy K.; Mazcko, Christina N.; Cherukuri, Aswini; Berger,Erika; Kisseberth, William C.; Brown, Megan E.; Lana, Susan E.; Weishaar, Kristen; Flesner, Brian K.; Bryan, Jeffrey N.; Vail, David M.; Burton, Jenna H.; Willcox, Jennifer L.; Mutsaers, Anthony J.; Woods, J. Paul; Northrup, Nicole C.; Saba, Corey; Curran, Kaitlin M.; Leeper, Haley; Wilson-Robles, Heather; Wustefeld-Janssens, Brandan G.; Lindley, Stephanie; Smith, Annette N.; Dervisis, Nikolaos; Klahn, Shawna; Higginbotham, Mary Lynn; Wouda, Raelene M.; Krick, Erika; Mahoney, Jennifer A.; London, Cheryl A.; Barber, Lisa G.; Balkman, Cheryl E.; McCleary-Wheeler, Angela L.; Suter, Steven E.; Martin, Olya; Borgatti, Antonella; Burgess, Kristine; Childress, Michael O.; Fidel, Janean L.; Allstadt, Sara D.; Gustafson, Daniel L.; Selmic, Laura E.; Khanna, Chand; Fan, Timothy M.
  3. CLINICAL CANCER RESEARCH. 2021, Jun 1; 27: 3005-3016.
  1. 2.   MG-2477, a new tubulin inhibitor, induces autophagy through inhibition of the Akt/mTOR pathway and delayed apoptosis in A549 cells
  2. Viola, G.; Bortolozzi, R.; Hamel, E.; Moro, S.; Brun, P.; Castagliuolo, I.; Ferlin, M. G.; Basso, G.
  3. Biochemical Pharmacology. 2012, Jan; 83(1): 16-26.
  1. 3.   mTOR Kinase Inhibitor AZD8055 Enhances the Immunotherapeutic Activity of an Agonist CD40 Antibody in Cancer Treatment
  2. Jiang, Q.; Weiss, J. M.; Back, T.; Chan, T.; Ortaldo, J. R.; Guichard, S.; Wiltrout, R. H.
  3. Cancer Research. 2011, Jun; 71(12): 4074-4084.
  1. 4.   Control of proliferation in astrocytoma cells by the receptor tyrosine kinase/PI3K/AKT signaling axis and the use of PI-103 and TCN as potential anti-astrocytoma therapies
  2. Gursel, D. B.; Connell-Albert, Y. S.; Tuskan, R. G.; Anastassiadis, T.; Walrath, J. C.; Hawes, J. J.; Amlin-Van Schaick, J. C.; Reilly, K. M.
  3. Neuro-Oncology. 2011, Jun; 13(6): 610-621.
  1. 5.   Rapamycin Protects Mice from Staphylococcal Enterotoxin B-Induced Toxic Shock and Blocks Cytokine Release In Vitro and In Vivo
  2. Krakauer, T.; Buckley, M.; Issaq, H. J.; Fox, S. D.
  3. Antimicrobial Agents and Chemotherapy. 2010, Mar; 54(3): 1125-1131.
  1. 6.   The Neurofibromatosis Type 1 Tumor Suppressor Controls Cell Growth by Regulating Signal Transducer and Activator of Transcription-3 Activity In vitro and In vivo
  2. Banerjee, S.; Byrd, J. N.; Gianino, S. M.; Harpstrite, S. E.; Rodriguez, F. J.; Tuskan, R. G.; Reilly, K. M.; Piwnica-Worms, D. R.; Gutmann, D. H.
  3. Cancer Research. 2010, Feb; 70(4): 1356-1366.
  1. 7.   Resistance to IFN-alpha-Induced Apoptosis Is Linked to a Loss of STAT2
  2. Romero-Weaver, A. L.; Wang, H. W.; Steen, H. C.; Scarzello, A. J.; Hall, V. L.; Sheikh, F.; Donnelly, R. P.; Gamero, A. M.
  3. Molecular Cancer Research. 2010, Jan; 8(1): 80-92.
  1. 8.   Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced murine lung tumors
  2. Granville, C. A.; Warfel, N.; Tsurutani, J.; Hollander, M. C.; Robertson, M.; Fox, S. D.; Veenstra, T. D.; Issaq, H. J.; Linnoila, R. I.; Dennis, P. A.
  3. Clinical Cancer Research. 2007, Apr; 13(7): 2281-2289.
  1. 9.   Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma
  2. Rudelius, M.; Pittaluga, S.; Nishizuka, S.; Pham, T. H. T.; Fend, F.; Jaffe, E. S.; Quintanilla-Martinez, L.; Raffeld, M.
  3. Blood. 2006, Sep; 108(5): 1668-1676.
  1. 10.   Inhibiting hypoxia-inducible factor 1 for cancer therapy
  2. Melillo, G.
  3. Molecular Cancer Research. 2006, Sep; 4(9): 601-605.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel